PTO/SB/08a (01-10)

Approved for use through 07/31/2012 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number

Remove

	Application Number		10681634		
	Filing Date		2003-10-08		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor Math		ithew		
	Art Unit		3737		
	Examiner Name	Ramirez, John Fernando			
	Attorney Docket Number		138065-1 (15115US01)		

U.S. PATENTS

Examiner Initial*	Cite No	F	atent Number	Kind Code ¹	Issue D)ate	Name of Pate of cited Docu	entee or Applicant ment	Rele	es,Columns,Lines where vant Passages or Releves res Appear	
	1	6	674537	B2	2004-01	1-96	Kadowaki				
If you wisl	h to ad	ld a	dditional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	-	Add	
				U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	ło	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicar of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wisl	h to ad	ld a	dditional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	butto	on. Add	
					FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*						Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TE
	1	11-	017862	JP			1999-01-22	Canon Inc			
	2	088	36428	EP		B1	2004-10-20	Canon Kabushiki K	aisha		
If you wisl	h to ad	ld a	dditional Foreign Pa	atent Do	cument	citation	information pl	Lease click the Add	butto	n Add	_
				NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove	

Examiner Initials*	Cite No					
	1	Japanese Application No. 2004-294834 Office Addion (5 pages) (22DEC2011)				

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered Date Considered Date Considered Date Considered PEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include coor of his form with next communication to accilicant.

1 See Kind Codes of USPTO Patient Documents at www.lbstor.org/ / Fee Inter office that issued the document, by the two-letter code (WIPO Standard ST 31). * For apparence patent documents, the inclusion of the year of the sign) of the Emperor must precede the serial number of the patent document. Serial results are included in the document under WIPO Standard ST // if potantial - Applicant to its place a code must have the patent occurred under WIPO Standard ST // if potantial - Applicant to its place a code must have the patent occurred under WIPO Standard ST // if potantial - Applicant to its place a code must have the patent occurred under WIPO Standard ST // if potantial - Applicant to its place a code must have the patent occurred to the patent occurred under the patent occurred to the patent occu

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10681634			
Filing Date		2003-10-08			
First Named Inventor Mathe		ew .			
Art Unit		3737			
Examiner Name	Ramir	ez, John Fernando			
Attorney Docket Number		138065-1 (15115US01)			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information displacate statement. Con 27 CED 1 07(a)/1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Philip H. Shendan

None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.							
	Signature	/Philip H. Sheridan/	Date (YYYY-MM-DD)	2012-02-23			

Registration Number

59.918

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbrary, and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested more considerable or the patient of the patient of

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.